Global Expansion And Decentralized Testing Will Unlock Future Potential

Key Takeaways

• Expansion into global and underpenetrated markets, alongside demographic trends, positions QuidelOrtho for sustained diagnostic demand and stable long-term revenue streams.
  
• Operational efficiency, high-value diagnostics innovation, and improved customer satisfaction enhance margins, market share, and resilience against future industry challenges.
  
• Post-pandemic demand decline, product discontinuations, regional pricing pressures, integration challenges, and lagging innovation threaten revenue, margins, and competitive positioning.

Catalysts

Provides diagnostic testing solutions.

• Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China-where differentiated technology, low market share, and a large runway for immunoassay growth exist-positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.
  
• Acquisition of LEX Diagnostics and the planned commercialization of its rapid molecular point-of-care platform addresses the trend toward fast, decentralized testing and is likely to increase recurring revenues and enhance margins as high-value, high-velocity diagnostic solutions become more prevalent.
  
• Demographic shifts, including an aging global population and increasing prevalence of chronic and lifestyle diseases, support baseline volume growth in key QuidelOrtho diagnostic platforms spanning clinical chemistry, immunoassays, and molecular diagnostics, underpinning long-term, stable revenue streams.
  
• Continued operational improvements-such as indirect procurement cost reductions, manufacturing site consolidation, and successful ERP system integration-are yielding significant margin and EBITDA gains, with incremental savings expected to directly benefit net margins and EPS into 2026 and beyond.
  
• Strong and improving customer satisfaction, recognized by top service rankings, and strategic talent acquisition in regulatory affairs are likely to support customer loyalty and regulatory execution, helping defend and expand market share, thus providing resilience and future upside potential to earnings.

QuidelOrtho Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming QuidelOrtho's revenue will grow by 3.8% annually over the next 3 years.
• Analysts are not forecasting that QuidelOrtho will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate QuidelOrtho's profit margin will increase from -45.6% to the average US Medical Equipment industry of 11.8% in 3 years.
• If QuidelOrtho's profit margin were to converge on the industry average, you could expect earnings to reach $349.5 million (and earnings per share of $5.06) by about July 2029, up from -$1.2 billion today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 5.7x on those 2029 earnings, up from -1.0x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.2x.
• Analysts expect the number of shares outstanding to grow by 0.43% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 11.8%, as per the Simply Wall St company report.

Risks

• Post-pandemic normalization is creating persistent drag on QuidelOrtho's revenues and profit margins, with COVID-related revenue falling sharply (COVID testing revenue down 52% YoY, and 2025 full year COVID guidance reduced by $40 million) and no new expected drivers to offset this high-margin product line; this directly threatens both top-line revenue and net margins.
  
• The winding down and discontinuation of certain product lines-such as the Donor Screening business and the Savanna molecular platform (which triggered $150 million in non-cash charges and eliminates future cash flows from those assets)-highlights risks in portfolio concentration and product obsolescence, ultimately reducing future revenue diversification and potentially impacting future earnings and profitability.
  
• Shifts in healthcare purchasing behavior in key international markets, particularly China, including volume-based procurement (VBP), reimbursement changes, and potential panel unbundling (DRG) processes, pose ongoing risks of price erosion and volume pressure; while the company claims limited near-term impact, further expansion in China may be constrained by these secular and regulatory headwinds, risking long-term revenue and margin growth in that region.
  
• Execution risk from large-scale integrations (such as the ongoing integration of Ortho Clinical and planned acquisition of LEX Diagnostics) could lead to elevated costs, operational disruptions, or delays in achieving anticipated synergies; additional restructuring charges and slow synergy realization may compress margins and negatively impact net earnings.
  
• Intensifying industry competition and rapid shifts toward decentralized, point-of-care, and next-generation diagnostic technologies may outpace QuidelOrtho's current R&D and platform upgrades (evidenced by recent product discontinuations and reliance on yet-to-be-approved new platforms like LEX), increasing the risk of market share loss, revenue declines, and the need for higher R&D spending that weighs on overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $20.5 for QuidelOrtho based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $12.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.0 billion, earnings will come to $349.5 million, and it would be trading on a PE ratio of 5.7x, assuming you use a discount rate of 11.8%.
• Given the current share price of $17.89, the analyst price target of $20.5 is 12.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.